• Rockwool International A/S v. Knauf Insulation, Inc. And Knauf Insulation SPRLInstitution denied
  PTAB · Jul 6, 2022 · PGR2022-00022 · APJ Elizabeth M Roesel · PGR · Institution

  The Board denied institution because Petitioner failed to establish that the ’629 Patent was eligible for post-grant review.

  RulingsInstitution decision

  • PTAB / AIA Trials › Institution threshold (reasonable likelihood / more likely than not)Institution denied meritsInstitution denied

    “Determining whether a patent is subject to the first-inventor-to-file provisions of the AIA, and therefore eligible for post-grant review, is straightforward when the challenged patent issued from an application filed before March 16, 2013, or when the challenged patent issued from an application filed on or after March 16, 2013, without any priority claim. The determination is more complex, however, for a patent that issues from a “transition application,” that is, an application filed on or after March 16, 2013, that claims the benefit of an earlier filing date. See MPEP § 2159.04.3 Entitlement to the benefit of an earlier filing date under 35 U.S.C. §§ 119, 120, 121, or 365 is premised on disclosure of the claimed invention “in the manner provided by § 112(a) (other than the requirement to disclose the best mode)” in the earlier application. See 35 U.S.C. §§ 119(e)(1), 120. Thus, for a patent issuing from a transition application, eligibility for post-grant review depends on whether the patent contains or contained at any time a claim that lacks written description or enabling support in a priority application filed before March 16, 2013.” slip op. at 5

  • Disclosure Requirements (§112) › Written description (Ariad)Written description adequateNot shown unpatentable

    “We agree with Patent Owner that Petitioner disregards the second part of the Federal Circuit’s two-part test by failing to address whether the specification of the ’629 Patent discloses structural features common to the members of the alleged genus. Prelim. Resp. 15–16; see Pet. 39 (quoting AbbVie, but omitting the two-part test). More fundamentally, however, we determine that Petitioner fails to establish that the claims of the ’629 Patent recite a “functionally-defined genus” that would trigger the application of the Federal Circuit’s two-part test. Ajinomoto, 932 F.3d at 1358, 1360; AbbVie, 759 F.3d at 1299; Ariad, 598 F.3d at 1349. Petitioner fails to show that the ’629 Patent claims recite a functionally-defined genus. Petitioner asserts that “claim 1 of the ’629 Patent claims a genus range of acceptable proportions of sugar reactants and amine reactants to the overall binder reactants.” Pet. 39. We agree with Patent Owner, however, that the limitations that Petitioner characterizes as a “genus range” are structural, not functional. See PO Resp. 17 (asserting that “[t]he claims themselves identify the[] common ‘structural features,’ specifying the ‘percent by dry weight’ of the ‘reducing sugar reactant’ and ‘amine reactant’ in the ‘binder solution’ used in the claimed method,” citing Ex. 1001, 6:4–11)).” slip op. at 13

  § 112 disclosure
  Patents in suitUS 10,968,629

Holdings, summaries, rulings, issues, outcomes, winners and claim constructions shown for a decision were generated by a large language model reading the opinion. They are a guide to the decision, not the decision. Confirm every one against the court's own text before relying on it. Outcomes read from the patent owner’s side. Party names are extracted from the decision and are missing on about 900 short Director denials and scans, which carry the trial number instead.